JP7385191B2 - Eml4-alk阻害ペプチドおよびこれを含む肺がん治療薬 - Google Patents
Eml4-alk阻害ペプチドおよびこれを含む肺がん治療薬 Download PDFInfo
- Publication number
- JP7385191B2 JP7385191B2 JP2019157950A JP2019157950A JP7385191B2 JP 7385191 B2 JP7385191 B2 JP 7385191B2 JP 2019157950 A JP2019157950 A JP 2019157950A JP 2019157950 A JP2019157950 A JP 2019157950A JP 7385191 B2 JP7385191 B2 JP 7385191B2
- Authority
- JP
- Japan
- Prior art keywords
- alk
- peptide
- eml4
- lys
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 87
- 230000002401 inhibitory effect Effects 0.000 title claims description 51
- 208000020816 lung neoplasm Diseases 0.000 title claims description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims description 18
- 201000005202 lung cancer Diseases 0.000 title claims description 18
- 239000012830 cancer therapeutic Substances 0.000 title claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 235000018977 lysine Nutrition 0.000 claims description 13
- 239000000178 monomer Substances 0.000 claims description 10
- 125000006850 spacer group Chemical group 0.000 claims description 10
- 239000004472 Lysine Substances 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 8
- 125000000524 functional group Chemical group 0.000 claims description 6
- 229940126585 therapeutic drug Drugs 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 150000002669 lysines Chemical class 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 28
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 26
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 230000027455 binding Effects 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 108091000080 Phosphotransferase Proteins 0.000 description 14
- 102000020233 phosphotransferase Human genes 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- WBSCNDJQPKSPII-UHFFFAOYSA-N 6-amino-2-[[6-amino-2-(2,6-diaminohexanoylamino)hexanoyl]amino]hexanoic acid Chemical group NCCCCC(N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(O)=O WBSCNDJQPKSPII-UHFFFAOYSA-N 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 8
- 229960005061 crizotinib Drugs 0.000 description 8
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 6
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 3
- 101710203446 Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Description
配列番号1:Gly-Glu-Glu-Pro-Ile-Phe-Trp-Ser-Phe-Pro-Ala(GEEPIFWSFPA)
のアミノ酸配列のC末端側に、リジン(Lys)を含む1~3のアミノ酸残基が結合しているペプチドモチーフを1以上含んでいる。
配列番号2:Gly-Glu-Glu-Pro-Ile-Phe-Trp-Ser-Phe-Pro-Ala-Lys(GEEPIFWSFPAK)
であることが好ましい。
スクリーニングに使用するALKキナーゼドメイン(ALK-KD、EML4-ALKの配列中N末端から534-849)はC末端にHis-tagを導入したものを用い、Bac to Bacバキュロウイルス発現系を用いて大量調製を行った。
配列番号1:Gly-Glu-Glu-Pro-Ile-Phe-Trp-Ser-Phe-Pro-Ala(GEEPIFWSFPA)
のアミノ酸配列のC末端側に、リジン(Lys)を含むアミノ酸残基(KKK、AKK、KAK、KKA、AAK、AKA、KAA)が結合しているペプチドは、ALK-KDとの結合活性に優れていることが確認された。
配列番号2:Gly-Glu-Glu-Pro-Ile-Phe-Trp-Ser-Phe-Pro-Ala-Lys(GEEPIFWSFPAK)
を新たに同定することができた。
マウスpro-B細胞株であるBa/F3細胞はIL3依存的な増殖能を示し、IL3非存在下では増殖することができないが、Ba/F3細胞に全長のEML4-ALK遺伝子を導入して作成したEML4-ALK安定発現細胞株(Ba/F3-ALK)は、IL3非依存的な増殖活性を示すようになる。Ba/F3-ALK細胞を0.1×106 cells/ml の濃度で96well plate にて、各種ペプチド存在下(0.03μM)で培養した。各日数培養後細胞を一部回収し、トリパンブルー染色後生細胞数を測定することで、Ba/F3-ALKのIL3非依存的な増殖に対する各種ペプチドの効果を検討した。なお、これまでの結果から、C末端のLysの重要性が示されたことから、配列番号2のアミノ酸配列のC末端のLysをAlaに置換したモノマーペプチド(IFA-mono)の阻害効果も合わせて評価した。さらに、IFK-monoならびにIFA-monoには、細胞膜透過性を付与する目的でN末端にミリストイル基を導入した(myr-IFK-mono, myr-IFA-mono)。
Claims (5)
- 配列番号1のアミノ酸配列のC末端側にリジン(Lys)を含む1~3つのアミノ酸残基が結合しているペプチドモチーフからなるモノマーペプチド、または、
配列番号1のアミノ酸配列のC末端側にリジン(Lys)を含む1~3つのアミノ酸残基が結合しているペプチドモチーフのN末端側に膜透過性のアミノ酸配列または官能基が連結したモノマーペプチド
であることを特徴とするEML4-ALK阻害ペプチド。 - 前記ペプチドモチーフは、配列番号2のアミノ酸配列からなることを特徴とする請求項1または2のEML4-ALK阻害ペプチド。
- 前記ペプチドモチーフのN末端側に、膜透過性のアミノ酸配列または官能基を有していることを特徴とする請求項2のEML4-ALK阻害ペプチド。
- EML4-ALKが発現している肺がんの治療薬であって、
請求項1から4のいずれかのEML4-ALK阻害ペプチドを含むことを特徴とする肺がん治療薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019157950A JP7385191B2 (ja) | 2019-08-30 | 2019-08-30 | Eml4-alk阻害ペプチドおよびこれを含む肺がん治療薬 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019157950A JP7385191B2 (ja) | 2019-08-30 | 2019-08-30 | Eml4-alk阻害ペプチドおよびこれを含む肺がん治療薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021035925A JP2021035925A (ja) | 2021-03-04 |
JP7385191B2 true JP7385191B2 (ja) | 2023-11-22 |
Family
ID=74716730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019157950A Active JP7385191B2 (ja) | 2019-08-30 | 2019-08-30 | Eml4-alk阻害ペプチドおよびこれを含む肺がん治療薬 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7385191B2 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005501047A (ja) | 2001-07-26 | 2005-01-13 | ペプター リミテッド | ペプチド又はペプチド模倣物質と結合したatp模倣物質を含むプロテインキナーゼ阻害剤 |
JP2008295444A (ja) | 2006-10-11 | 2008-12-11 | Astellas Pharma Inc | Eml4−alk融合遺伝子 |
US20090156475A1 (en) | 2006-04-14 | 2009-06-18 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
JP2010501175A (ja) | 2007-04-13 | 2010-01-21 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト固形腫瘍における遺伝子欠失及び突然変異alkキナーゼ |
JP2011511949A (ja) | 2008-02-12 | 2011-04-14 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 肺癌におけるeml4とalkの融合のためのfishアッセイ |
JP2015228860A (ja) | 2014-06-08 | 2015-12-21 | 国立大学法人金沢大学 | A925l由来癌細胞株 |
JP2017511314A (ja) | 2014-03-28 | 2017-04-20 | アクセレロン ファーマ インコーポレイテッドAcceleron Pharma,Inc. | 癌の処置におけるアクチビン受容体様キナーゼ1(alk−1)アンタゴニストの使用 |
-
2019
- 2019-08-30 JP JP2019157950A patent/JP7385191B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005501047A (ja) | 2001-07-26 | 2005-01-13 | ペプター リミテッド | ペプチド又はペプチド模倣物質と結合したatp模倣物質を含むプロテインキナーゼ阻害剤 |
US20090156475A1 (en) | 2006-04-14 | 2009-06-18 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
JP2008295444A (ja) | 2006-10-11 | 2008-12-11 | Astellas Pharma Inc | Eml4−alk融合遺伝子 |
JP2010501175A (ja) | 2007-04-13 | 2010-01-21 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト固形腫瘍における遺伝子欠失及び突然変異alkキナーゼ |
JP2011511949A (ja) | 2008-02-12 | 2011-04-14 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 肺癌におけるeml4とalkの融合のためのfishアッセイ |
JP2017511314A (ja) | 2014-03-28 | 2017-04-20 | アクセレロン ファーマ インコーポレイテッドAcceleron Pharma,Inc. | 癌の処置におけるアクチビン受容体様キナーゼ1(alk−1)アンタゴニストの使用 |
JP2015228860A (ja) | 2014-06-08 | 2015-12-21 | 国立大学法人金沢大学 | A925l由来癌細胞株 |
Also Published As
Publication number | Publication date |
---|---|
JP2021035925A (ja) | 2021-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7943581B2 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
US11220532B2 (en) | Targeting deregulated Wnt signaling in cancer using stabilized alpha-helices of BCL-9 | |
CA2632451C (en) | Cell penetrating peptides for intracellular delivery of molecules | |
PT2352508E (pt) | Péptidos do domínio citoplasmático muc1 como inibidores de cancro | |
US20080248008A1 (en) | Inhibitors of Protein Kinase a Anchoring | |
EP1795539B1 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
KR102042015B1 (ko) | 폐 손상, 천식, 과민증, 혈관 부종, 전신 혈관 투과성 증후군 및 비충혈을 치료하는 펩티드 조성물과 이들로 이러한 질환을 치료하는 방법 | |
JP7385191B2 (ja) | Eml4-alk阻害ペプチドおよびこれを含む肺がん治療薬 | |
Nozaki et al. | Borealin-derived peptides as survivin-targeting cancer imaging and therapeutic agents | |
JP6660966B2 (ja) | B型肝炎ウイルスxタンパク質に対するポリペプチド薬物 | |
US9526757B2 (en) | Peptides that inhibit the interaction between ASF1 and histones, and use thereof | |
WO2021246265A1 (ja) | S100a8阻害ペプチドとこれを含む疾患治療薬 | |
JP7156635B2 (ja) | 破骨細胞分化制御ペプチド、および、破骨細胞分化に関連する疾患の含有する治療薬 | |
KR100409264B1 (ko) | 세포내 신호전달을 교란시키는 합성 펩티드 | |
WO2014164394A1 (en) | Combination anti-her2 cancer therapy using muc1 peptides and chemotherapeutics | |
JP5852731B2 (ja) | 高増殖性疾患治療のための医薬組成物 | |
US11965011B2 (en) | Antitumor peptide and use thereof | |
JP2020075917A (ja) | p210 PH結合ペプチドおよび慢性骨髄性白血病治療薬 | |
RU2728870C2 (ru) | Полипептиды для лечения онкологических заболеваний | |
KR20230006581A (ko) | 고형암의 치료에 사용하기 위한 pcna 상호작용 모티프를 함유하는 펩티드 | |
Dulsat | European Association for Cancer Research (EACR)–28th Annual Meeting. Seville–June 20-23, 2022 | |
DK2578227T3 (en) | METHOD OF CANCER THERAPY | |
KR20210135186A (ko) | Ask1 억제제 및 그 용도 | |
JPWO2006132245A1 (ja) | 腫瘍増殖抑制剤 | |
JP2016520547A (ja) | 腫瘍性疾患を治療するためのキメラペプチド及び医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20220801 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220802 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230627 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230809 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230926 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231024 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231031 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7385191 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |